FIELD: chemistry; pharmacy.
SUBSTANCE: invention concerns new compounds of formula I: 
, where W is 
, X is N or C-R1; R is C1-C7alkyl, C3-C7cycloalkyl, (C1-C7alkylene)-(C3-C7cycloalkyl), -SO2-(C1-C7alkyl) or -SO2-NR5R6; R1 is hydrogen, amino, methyl or -N=CH(NMe)2; R is phenyl optionally substituted by one or more substitutes selected independently out of halogen; R3 is hydrogen, C1-C7alkyl, C3-C7cycloalkyl or phenyl optionally substituted by one or more substitutes selected independently out of halogen and trifluoromethyl; R4 is hydrogen or C1-C7alkyl; R5 and R6 are independently selected out of group including C1-C7alkyl; and its pharmaceutically acceptable salts. Also invention concerns pharmaceutical composition and application.
EFFECT: obtaining new bioactive compounds with inhibition effect on kinase p-38.
10 cl, 114 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROARYL COMPOUNDS AS TKB INHIBITORS AND USE THEREOF | 2015 |
|
RU2742122C2 |
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| IMIDAZO-ANNELATED ISO- AND HETEROCYCLES AND METHOD FOR THEIR PRODUCTION | 1992 |
|
RU2076105C1 |
| SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | 2013 |
|
RU2690663C2 |
| 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2021 |
|
RU2822180C1 |
| XIA FACTOR INHIBITORS | 2016 |
|
RU2728783C2 |
| HETEROARYL COMPOUNDS, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATING WITH USE OF SUCH COMPOUNDS | 2007 |
|
RU2478635C2 |
| MACROCYCLIC TYROSINE KINASE INHIBITOR AND ITS USE | 2019 |
|
RU2798231C2 |
| TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
| DERIVATIVES OF 1,2,4-TRIAZINE-4-AMINE | 2011 |
|
RU2625791C2 |
